drugset / Trial / NCT01004419
Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer
Phase 1
Withdrawn
University of Wisconsin, Madison
AstraZeneca · collabUniversity of Pittsburgh · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of vandetanib and fulvestrant; to find the maximum tolerated dose of these two drugs; and to evaluate response rate and assess toxicity of this combination.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-11
- Completion
- 2011-05
Outcome
Outcome not reported
Stopped: “Support for investigational products has been withdrawn.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Vandetanib | Small molecule | 100 mg | Oral |
| Subject | Vandetanib | Small molecule | 200 mg | Oral |
| Subject | Vandetanib | Small molecule | 300 mg | Oral |